Core Viewpoint - The announcement indicates that Changfeng Pharmaceutical, a company in which Shuanglu Pharmaceutical holds a stake, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, under the stock code 02652.HK [1] Summary by Relevant Categories Company Information - Shuanglu Pharmaceutical holds 15,165,700 shares in Changfeng Pharmaceutical, which is expected to represent 3.68% of the total shares post-issuance [1] - Changfeng Pharmaceutical plans to globally offer 41,198,000 shares at a price of HKD 14.75 per share [1] Market Impact - The listing of Changfeng Pharmaceutical is anticipated to enhance Shuanglu Pharmaceutical's visibility and potential market valuation [1]

一、参股公司上市情况概述 北京双鹭药业股份有限公司（以下简称"公司"）参股公司长风药业股份有限公司（以 下简称"长风药业"）预计于 2025 年 10 月 8 日正式在联交所挂牌上市，股份代号为 02652.HK。 根据长风药业全球发售招股书之披露，其本次全球发售 4119.8 万股，发售价格为每股 14.75 港元。长风药业在香港上市的详细内容可在香港联交所网站（www.hkexnews.hk）查阅。 证券代码：002038 证券简称：双鹭药业 公告编号：2025-030 北京双鹭药业股份有限公司关于参股公司长风 药业股份有限公司拟在香港联交所主板挂牌上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 北京双鹭药业股份有限公司董事会 二〇二五年九月三十日 二、公司持股情况 长风药业本次发售完成后，本公司持有的其股份总数为 1,516.5653 万股，预计占其发行 后总股份数的 3.68%，本公司持有的长风药业股份的禁售期为长风药业上市后 12 个月。 三、对公司的影响 根据《企业会计准则》相关规定，公司对所持长风药业的股权划分为"以公允价值计量 且其 ...

Core Insights - Alkylating agents are essential cytotoxic drugs primarily used for treating malignant lymphomas and chronic lymphocytic leukemia, with increasing demand due to rising global cancer incidence [1][2][4] - The global alkylating agent market is projected to grow from $2.23 billion in 2015 to $3.19 billion in 2024, while China's market is expected to increase from ¥7.46 billion to ¥12.26 billion in the same period [1][5] Alkylating Agent Industry Definition and Classification - Alkylating agents, also known as biological alkylating agents, are a crucial class of antitumor drugs that work by damaging DNA structure and function, inhibiting the proliferation of rapidly dividing cells like cancer cells [2][6] - Common alkylating agents include cyclophosphamide, nitrogen mustard, and temozolomide, with cyclophosphamide being the most widely used in clinical settings [2][6] Current Development Status of Alkylating Agent Industry - The demand for alkylating agents is increasing due to the rising incidence of cancer, with over 4.5 million new cancer cases reported annually in China [6][8] - The Chinese alkylating agent market is expected to reach ¥12.61 billion by 2025, reflecting a stable growth trajectory supported by government policies [5][11] Alkylating Agent Industry Chain - The upstream of the alkylating agent industry includes basic chemical raw materials and key intermediates, while the midstream focuses on the production of alkylating agents concentrated in major industrial clusters [5][6] - The downstream market primarily serves hospitals and specialized cancer treatment centers, catering to patients with various types of cancers [5][6] Competitive Landscape of Alkylating Agent Industry - Major companies in the alkylating agent sector include Hengrui Medicine, Beijing Double-Crane Pharmaceutical, and Jiangsu Hengrui Medicine, among others [2][8] - Hengrui Medicine has a strong product matrix with 19 new molecular entities approved in China and a significant focus on oncology [9][10] Development Trends in Alkylating Agent Industry - The demand for alkylating agents is expected to grow due to advancements in the pharmaceutical sector, with a focus on technological innovation and improved production processes [11][12] - The industry is moving towards greener, smarter, and higher-quality production methods to meet increasing market demands [11][12]

Core Viewpoint - The chemotherapy drug market in China is experiencing growth due to increasing cancer patient numbers and rising consumer spending, despite competition from targeted therapies. Chemotherapy drugs remain dominant due to their stable efficacy, broad anti-cancer properties, and relatively low prices [1][4][5]. Group 1: Industry Overview - Chemotherapy drugs are a crucial method for cancer treatment, classified into various types such as alkylating agents, antimetabolites, and plant-derived anticancer drugs [2][3]. - The demand for chemotherapy drugs in China is projected to reach 3.858 billion units with a market size of 135.59 billion yuan in 2024, led by plant alkaloids and antimetabolites [5][6]. - The global chemotherapy drug market is expected to grow from 33.53 billion USD in 2024 to 36.84 billion USD in 2025, with the Asia-Pacific region holding a significant share [4][5]. Group 2: Market Dynamics - The Chinese chemotherapy drug market is characterized by a dual driving force of strong demand for certain drug types while facing pressure from generics and targeted therapies [5][10]. - The production of chemotherapy drugs in China is anticipated to increase to 3.432 billion units by 2025, reflecting a growth trend in domestic manufacturing capabilities [6][10]. - The competitive landscape is intensifying with local companies like Heng Rui Medicine and Qilu Pharmaceutical making significant strides in both generic and innovative drug development [10][11]. Group 3: Regulatory Environment - The Chinese government has implemented supportive policies to encourage the development of innovative cancer treatment drugs, providing a favorable environment for industry growth [8][9]. - The industry is witnessing accelerated drug approval processes and procurement policies that favor local manufacturers, enhancing competition [10][11]. Group 4: Future Trends - The chemotherapy drug sector is expected to evolve towards precision medicine, with advancements in targeted therapies and combination treatments [11]. - Innovations in drug delivery systems, such as nanotechnology, are anticipated to enhance treatment efficacy and patient outcomes [11].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、关于非独立董事辞职的基本情况 北京双鹭药业股份公司（以下简称"公司"）董事会于近日收到非独立董事陈玉林先生提交的书面辞职报 告。陈玉林先生因年龄原因申请辞去公司第九届董事会非独立董事、提名委员会委员职务，辞任后，陈 玉林先生不再担任公司及控股子公司其他职务。根据《中华人民共和国公司法》（以下简称《公司 法》）、《深圳证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作（2025年修 订）》、《北京双鹭药业股份公司章程》（以下简称《公司章程》）等相关规定，陈玉林先生的辞任会 导致董事会成员及提名委员会成员低于法定最低人数，其辞职报告于公司聘任新的董事后生效。陈玉林 先生的辞任不会影响公司董事会的正常运行，亦不会对公司正常的经营发展产生影响。 陈玉林先生在担任公司董事期间恪尽职守、勤勉尽责，公司对其任职期间为公司发展所做的贡献表示衷 心感谢。 二、关于选举职工代表董事的情况说明 根据《公司法》、《深圳证券交易所股票上市规则》和《公司章程》等相关规定，公司对 ...

证券日报网讯9月23日晚间，双鹭药业（002038）发布公告称，公司董事会于近日收到非独立董事陈玉 林先生提交的书面辞职报告。陈玉林先生因年龄原因申请辞去公司第九届董事会非独立董事、提名委员 会委员职务，辞任后，陈玉林先生不再担任公司及控股子公司其他职务。 ...

证券日报网讯 9月23日晚间，双鹭药业（002038）发布公告称，公司于2025年9月23日召开公司2025年 职工代表大会第一次会议。经公司与会职工代表表决通过，选举齐燕明女士为公司第九届董事会职工代 表董事、提名委员会委员。 ...

南财智讯9月23日电，双鹭药业公告，非独立董事陈玉林先生因年龄原因提交了书面辞职报告，辞职后 将不再担任公司及控股子公司任何职务。根据相关规定，其辞职需待新董事聘任后方能生效。同时，公 司选举齐燕明女士为新的职工代表董事及提名委员会委员，任期至第九届董事会任期届满。齐燕明女士 具备相应的任职资格，符合相关法律法规的要求。 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2025-029 北京双鹭药业股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 大会审议通过之日起至第九届董事会任期届满为止。齐燕明女士原为公司第九届监事会主席， 熟悉劳动法相关规定及公司规章制度，能够代表和反映职工的意见和要求，具备参与经营决 策和协调沟通的能力，能够在董事会决策中有效维护职工合法权益，符合《公司法》等法律 法规和《公司章程》规定的任职条件。 本次职工代表董事候选人具备与其行使职权相适应的任职条件，与持有公司 5%以上股 份的股东及公司其他董事、高级管理人员不存在关联关系，未受过中国证监会及其他有关部 门的处罚和证券交易所纪律处分，不存在因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规 被中国证监会立案稽查，尚未有明确结论的情形，不存在被中国证监会在证券期货市场违法 失信信息公开查询平台公示或者被人民法院纳入失信被执行人名单的情形，符合有关法律、 行政法规、部门规章、规范性文件、《股票上市规则》、《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作（2025 年修订）》及交易所其它相关规定和公司 章程等要求的任职资 ...

证券日报网讯双鹭药业（002038）9月22日在互动平台回答投资者提问时表示，公司年报中主要在研的 品种都已列示，公司后续开发的重点产品包括长、短效重组人促卵胞激素注射液、DT678、DT109、 0101滴眼剂、GLP-1-Fc融合蛋白等。 ...